1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20665
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorLianos, E.en
dc.contributor.authorBobos, M.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorGogas, H.en
dc.contributor.authorRazis, E.en
dc.contributor.authorSkarlos, D. V.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:09:10Z-
dc.date.available2015-11-24T19:09:10Z-
dc.identifier.issn1423-0232-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20665-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibodies, Monoclonal/*administration & dosage/adverse effectsen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectBreast Neoplasms/chemistry/*drug therapy/mortalityen
dc.subjectDoxorubicin/administration & dosage/adverse effects/*analogs & derivativesen
dc.subjectHumansen
dc.subjectMiddle Ageden
dc.subjectPTEN Phosphohydrolase/analysisen
dc.subjectPolyethylene Glycols/*administration & dosage/adverse effectsen
dc.subjectProtein Kinases/analysisen
dc.subjectReceptor, erbB-2/analysisen
dc.subjectTOR Serine-Threonine Kinasesen
dc.subjectVentricular Function, Left/drug effectsen
dc.titleTrastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluationen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1159/000207504-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19262067-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000207504-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractOBJECTIVE: Combination of trastuzumab and anthracyclines in metastatic breast cancer (MBC) is precluded due to cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of trastuzumab and PLD with biomarker evaluation. METHODS: Patients with MBC and HER2 overexpression, assessed as 3+ at local laboratories, received trastuzumab 8 mg/kg as loading dose followed by 6 mg/kg in combination with PLD 30 mg/m(2), both given every 3 weeks. To be eligible, patients should have received first-line chemotherapy for MBC or should have relapsed within a year of adjuvant taxane. Tumor tissue blocks were collected for central review and exploratory biomarker evaluation. Left-ventricular ejection fraction (LVEF) was closely monitored by cardiac ultrasound. RESULTS: Among 37 patients, an overall response rate of 22% was observed with a progression-free survival (PFS) of 6.5 months (0.8-31.1, 95% CI 2.7-10.3) and a survival of 18.7 months (1.6-40.8, 95% CI 3.7-33.7). No decline in LVEF was noticed. Overexpression of mTOR and TOP2A gene alterations were associated with better PFS. PTEN gene deletion was associated with resistance to treatment. CONCLUSION: Trastuzumab combined with PLD every 3 weeks is feasible, effective and safe in HER2-positive patients.en
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons